Trials / Completed
CompletedNCT01901692
Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion
Randomized Trial Comparing Sorafenib and Transarterial Chemoembolization Plus External Beam Radiotherapy in Patients With Hepatocellular Carcinoma Showing Macroscopic Vascular Invasion
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate and compare the efficacy and safety of sorafenib versus trans-arterial chemoembolization plus external beam radiation therapy in patients with hepatocellular carcinoma invading major intrahepatic vessels
Detailed description
Current practice guidelines recommend only sorafenib for patients with hepatocellular carcinoma invading major intrahepatic vessels. However, recent data from observational studies suggest that the combination of transarterial chemoembolization and external beam radiotherapy would be as effective as sorafenib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | TACE+External beam RT | Trans-arterial chemoembolization (TACE) every 6 weeks + external beam radiation therapy starting within 3 weeks after first TACE |
| DRUG | Sorafenib | Sorafenib 800 mg/day orally |
Timeline
- Start date
- 2013-07-29
- Primary completion
- 2017-01-20
- Completion
- 2017-08-31
- First posted
- 2013-07-17
- Last updated
- 2017-09-18
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01901692. Inclusion in this directory is not an endorsement.